Week 33 topline data showed 22 percent weight loss with no plateau observed for Viking Therapeutics candidate VK2735. VKTX stock moved little after the release. The disconnect between clinical durability and market pricing is forcing a rethink of GLP-1 valuation models.
💡 Frequently Asked Questions (FAQ)
- Q: Why did VKTX stock move little after the 22% weight loss data?
- A: The market appeared cautious despite strong topline results, likely pricing in execution risk, trial stage, and competitive GLP-1 dynamics rather than clinical durability alone.
- Q: What does ‘no plateau’ mean for Viking’s VK2735?
- A: No plateau means weight loss continued through week 33 without flattening, suggesting sustained efficacy and potential durability advantage versus peers in the GLP-1 class.
- Q: How could this data change GLP-1 valuation models?
- A: Durable, plateau-free weight loss challenges models based on short-term efficacy and peak sales, pushing investors to revalue assets on long-term clinical differentiation and persistence.